• Je něco špatně v tomto záznamu ?

Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review

K. Rebhan, G. Wasinger, MR. Hassler, SF. Shariat, EM. Compérat

. 2022 ; 32 (4) : 358-363. [pub] 20220701

Jazyk angličtina Země Spojené státy americké

Typ dokumentu kazuistiky, časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22017871

PURPOSE OF REVIEW: Due to the limited number of cases, there are no guidelines for basal cell carcinoma (BCC) of the prostate. This review combines an unpublished case report of a 55-year-old patient with BCC with an assessment of the latest literature. RECENT FINDINGS: BCC of the prostate has previously been described in only approximately 140 cases. We describe the diagnostic process, including the uropathological and DNA-sequencing results, which allowed us to start an experimental treatment with pemigatinib. BCC of the prostate is associated with an aggressive biological and clinical behavior, such as recurrence and metastasis. Several immunohistochemical stainings are available to differentiate BCC from adenocarcinoma of the prostate. Based on pathology and results from next-generation sequencing (NGS), patients can be offered targeted therapies. SUMMARY: With the aid of histological work-up and immunostaining, prostatic BCC can be accurately diagnosed. Our patient underwent radical prostatectomy and staged extended lymphadenectomy due to lymph node recurrence. The patient subsequently developed progressive disease and was treated with the FGFR-inhibitor pemigatinib. The patient's liver metastasis significantly responded. The present case confirms the possibility of aggressive behavior of prostatic BCC and highlights the importance of a thorough uropathological and molecular biological analysis with a precision medicine strategy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017871
003      
CZ-PrNML
005      
20220804134432.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MOU.0000000000001007 $2 doi
035    __
$a (PubMed)35749783
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rebhan, Katharina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna
245    10
$a Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review / $c K. Rebhan, G. Wasinger, MR. Hassler, SF. Shariat, EM. Compérat
520    9_
$a PURPOSE OF REVIEW: Due to the limited number of cases, there are no guidelines for basal cell carcinoma (BCC) of the prostate. This review combines an unpublished case report of a 55-year-old patient with BCC with an assessment of the latest literature. RECENT FINDINGS: BCC of the prostate has previously been described in only approximately 140 cases. We describe the diagnostic process, including the uropathological and DNA-sequencing results, which allowed us to start an experimental treatment with pemigatinib. BCC of the prostate is associated with an aggressive biological and clinical behavior, such as recurrence and metastasis. Several immunohistochemical stainings are available to differentiate BCC from adenocarcinoma of the prostate. Based on pathology and results from next-generation sequencing (NGS), patients can be offered targeted therapies. SUMMARY: With the aid of histological work-up and immunostaining, prostatic BCC can be accurately diagnosed. Our patient underwent radical prostatectomy and staged extended lymphadenectomy due to lymph node recurrence. The patient subsequently developed progressive disease and was treated with the FGFR-inhibitor pemigatinib. The patient's liver metastasis significantly responded. The present case confirms the possibility of aggressive behavior of prostatic BCC and highlights the importance of a thorough uropathological and molecular biological analysis with a precision medicine strategy.
650    12
$a bazocelulární karcinom $x diagnóza $x patologie $x chirurgie $7 D002280
650    _2
$a lidé $7 D006801
650    _2
$a lymfadenektomie $7 D008197
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a morfoliny $7 D009025
650    _2
$a prostata $x patologie $7 D011467
650    _2
$a prostatektomie $7 D011468
650    12
$a nádory prostaty $x diagnóza $x farmakoterapie $x genetika $7 D011471
650    _2
$a pyrimidiny $7 D011743
650    _2
$a pyrroly $7 D011758
650    12
$a nádory kůže $x chirurgie $7 D012878
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Wasinger, Gabriel $u Department of Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Hassler, Melanie R $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna $u Departments of Urology, Weill Cornell Medical College, New York, New York $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
700    1_
$a Compérat, Eva M $u Department of Pathology, Medical University of Vienna, Vienna, Austria $u Department of Pathology, Sorbonne University, Assistance Publique-Hôpital de Paris, Hopital Tenon, Paris, France
773    0_
$w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 32, č. 4 (2022), s. 358-363
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35749783 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134426 $b ABA008
999    __
$a ok $b bmc $g 1821795 $s 1169114
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 32 $c 4 $d 358-363 $e 20220701 $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace